OSTEOPOROSIS TREATMENT MARKET ANALYSIS
Osteoporosis Treatment Market, by Drug Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, and Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, and Rank Ligand (RANKL) Inhibitor), by Route of Administration (Oral, Injectable, and Others), by Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Osteoporosis Treatment Market- Insights
Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake.

Moreover, conditions that increase the risk of osteoporosis include cancer, chronic kidney diseases, chronic obstructive pulmonary disease, and some autoimmune disease such as rheumatoid arthritis. Osteoporosis treatment involves preventing and treating fractures and using medication to strengthen bones.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/osteoporosis-treatment-market-1096

The treatment usually includes medications such as Bisphosphonates that are the most common drugs prescribed. Furthermore, hormone therapy treatment is recommended for post-menopausal women, as they experience a drop in the levels of estrogen, which weakens the bones.

Frequent launches and approvals of novel osteoporosis treatment drugs are expected to drive growth of the market

Key players in the market are focused on launching and receiving regulatory approval for novel osteoporosis drugs in the market, which are expected to boost the global osteoporosis treatment market growth. For instance, in 2016, EffRx Pharmaceuticals SA marketing partner of Ahn-Gook Pharmaceutical Co. Ltd. received Korean Ministry of Food and Drug Safety (MFDS) approval for its drug Binosto, a buffered solution indicated for the treatment of osteoporosis.

In 2013, Daiichi Sankyo Company Ltd. launched its drug PRALIA, a subcutaneous injection for the treatment of osteoporosis, in Japan. In May 2018, Amgen Inc. received the U.S. Food and Drug Administration approval for its drug Prolia indicated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.

The global osteoporosis treatment market size was valued at US$ 11.8 Bn in 2017, and is expected to exhibit a CAGR of 3.8% over the forecast period (2018-2026).

Increasing incidence of osteoporosis with rising geriatric population is expected to drive demand for osteoporosis treatment drugs

High prevalence and increased diagnosis of osteoporosis in geriatric population is expected to rise demand for osteoporosis drugs and fuel the osteoporosis treatment market growth. For instance, according to a report by United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific constituted around 60% of the world’s geriatric population. Moreover, around 547 million people were aged above 60 years in the region and this number is expected to double and reach around 1.3 billion by 2050.

Furthermore, key players are involved in strategic agreement for the development of novel osteoporosis drugs to launch in the market. For instance, in June 2018, Pfenex Inc. and Alvogen Inc. entered into strategic agreement for the development of Pfenex Inc.’s osteoporosis drug candidate PF708. According to the agreement, Pfenex’s granted exclusive rights to commercialize PF708 to Alvogen Inc.

Asia Pacific osteoporosis treatment market is expected to witness significant growth over the forecast period, owing to increasing strategic collaboration of key players with Asia Pacific companies for penetrating key regions in Asia Pacific and to expand its product presence. For instance, 2013, EffRx Pharmaceuticals SA entered into a collaboration with South Korea-based, Ahn-Gook Pharmaceutical Co. Ltd., for the distribution of Binosto osteoporosis drug in South Korea.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1096

Europe osteoporosis treatment market is expected to witness significant growth over the forecast period, owing to the penetration of key players in the region and focus of key players to receive approval for its new osteoporosis drugs in the market. For instance, in January 2018, the European Medicine Agency (EMA) accepted Amgen Inc. and Union Chiriquí Belge’s (UCB) submission to review their drug Evenity (romosozumab), an anabolic agent indicated for treatment of postmenopausal women and men with osteoporosis.

However, launch of generic versions of osteoporosis drugs is expected to restrain revenue growth of the osteoporosis treatment market, owing to low price of generic drugs as compared to branded. For instance, in 2015, Teva Pharmaceutical Industries Ltd. launched generic version of Actonel (risedronate sodium) Tablets, 5 mg, 30 mg, and 35 mg in the U.S. market. In 2012, Dr. Reddy's Laboratories launce its generic anti-osteoporosis drug Ibandronate Sodium, in 2012 Mylan Inc. received U.S. Food and Drug Administration approval for Ibandronate Sodium Tablets, 150mg, a generic version of F. Hoffmann-La Roche AG’s Boniva indicated for treatment of osteoporosis in postmenopausal women.

Key players operating in the global osteoporosis treatment market include Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Amgen Inc., Dr. Reddy's Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche AG, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co AG, GlaxoSmithKline Plc., Allergan plc., and Pfizer Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1096

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737